[发明专利]青蒿素在制备抗人肝癌HepG2和Huh7细胞药物的应用

权利要求书

1.青蒿素在制备抗人肝癌HepG2和Huh7细胞药物的应用，其特征在于：通过抑制人肝癌HepG2细胞和Huh7细胞的增殖，和/或，调整人肝癌HepG2细胞和Huh7细胞内的miRNA表达谱实现；所述青蒿素浓度≤100μM。

2.根据权利要求1所述的应用，其特征在于：所述抑制HepG2细胞增殖调控通过Rap1信号通路实现；所述抑制Huh7细胞增殖调控通过MAPK信号通路实现。

3.根据权利要求1所述的应用，其特征在于：

所述调整HepG2细胞的miRNA包括上调基因：hsa-miR-199a-5p；hsa-miR-29b-3p；hsa-miR-30e-5p；hsa-miR-135b-5p；hsa-miR-32-5p；hsa-miR-378a-3p；hsa-miR-4426；hsa-miR-1307-3p；hsa-miR-30a-5p；hsa-miR-200a-3p；hsa-miR-181d-5p；hsa-miR-363-3p；hsa-miR-29a-3p；novel_1144；hsa-miR-455-5p；hsa-miR-663a；hsa-miR-345-5p；hsa-miR-1273g-3p；hsa-miR-20a-5p；hsa-miR-1248；novel_1213；hsa-miR-140-5p；hsa-miR-199a-3p；hsa-miR-126-3p；hsa-miR-7704；hsa-miR-7641；hsa-miR-194-5p；hsa-miR-622；hsa-miR-28-5p；hsa-miR-17-5p；novel_1005；novel_827；novel_1212hsa-miR-429；hsa-miR-3184-5p；hsa-miR-423-3p；hsa-miR-22-3p；hsa-miR-125b-5p；hsa-miR-301a-3p；hsa-miR-15a-5p；hsa-miR-3064-5p；hsa-miR-3143；hsa-miR-7161-3p；

下调基因：hsa-miR-1257；hsa-let-7e-5p；hsa-miR-28-3p；hsa-miR-192-5p；hsa-miR-3184-3p；hsa-miR-423-5p；hsa-miR-10b-5p；hsa-miR-30e-3p；hsa-let-7f-5p；hsa-miR-455-3p；hsa-miR-3529-3p；hsa-miR-101-3p；hsa-miR-7-5p；hsa-miR-335-3p；hsa-miR-199b-5p；hsa-miR-1-3p；hsa-miR-4521；hsa-miR-651-5p；hsa-miR-182-5p；hsa-miR-584-5p；hsa-miR-23b-3p；hsa-miR-532-5p；hsa-miR-140-3p；hsa-miR-361-3p；hsa-miR-23a-3p；hsa-miR-4664-5p；hsa-miR-664a-3p；hsa-miR-33a-3p；hsa-miR-195-3p；hsa-miR-1299；hsa-miR-500a-3p；hsa-miR-215-5p；hsa-miR-3679-5p；hsa-miR-624-5p；hsa-miR-4454；hsa-miR-574-5p；hsa-miR-122-5p；hsa-miR-1276；hsa-miR-148a-5p；hsa-miR-3591-3p；hsa-miR-99b-3p。